Mednet Logo
HomeQuestion

How are you clinically incorporating the data presented from RT Charm at ASTRO 2024?

7
5 Answers
Mednet Member
Mednet Member
Radiation Oncology · University of Utah

This is an appropriate question with the presentation of RT CHARM at ASTRO a few weeks ago. We have been utilizing hypofractionated NON-reconstruction PMRT and regional nodal breast RT for years in my practice given our large geographic catchment area. As a general rule, I feel it's always best prac...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

Yes, routinely offering hypofractionation with RT CHARM and FABREC supporting it.

Register or Sign In to see full answer

Mednet Member
Mednet Member
Radiation Oncology · University of Texas at Tyler

Additional information on the safety of hypofractionated nodal radiotherapy recently emerged. The 2024 ESMO presentation 2310 of HypoG-01 solidifies the use of nodal hypofractionation as a safe method to treat the breast or chest wall and nodal basins. A broad range of stages, pT1-3 & pN0-3, HER2, r...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Radiation Oncology · Cooper Medical School of Rowan University/Cooper University Hospital

It’s becoming increasingly difficult to rationalize conventionally-fractionated radiotherapy for breast cancer.

Register or Sign In to see full answer

Mednet Member
Mednet Member
Radiation Oncology · University of Utah

RT CHARM is written and being submitted for publication.

Register or Sign In to see full answer

How are you clinically incorporating the data presented from RT Charm at ASTRO 2024? | Mednet